CSIMarket Company Name, Ticker, Industry, else..
 
Tonix Pharmaceuticals Holding Corp   (NASDAQ: TNXP)
 
Price: $11.6700 $-0.61 -4.967%
Day's High: $12.614999771118164 Week Perf: -11.19 %
Day's Low: $ 11.67 30 Day Perf: -2.51 %
Volume (M): 203,976 52 Wk High: $ 29.19
Volume (M$): $ 0 52 Wk Avg: $15.39
Open: $12.44 52 Wk Low: $9.40



 Market Capitalization (Millions $) 194
 Shares Outstanding (Millions) 17
 Employees 142
 Revenues (TTM) (Millions $) 29
 Net Income (TTM) (Millions $) -160
 Cash Flow (TTM) (Millions $) 60
 Capital Exp. (TTM) (Millions $) 5

Business Description


Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological disorders. The company's lead product candidate, TNX-102 SL, is a sublingual tablet formulation of cyclobenzaprine being developed for the treatment of posttraumatic stress disorder (PTSD), fibromyalgia, and agitation in Alzheimer's disease. Tonix also has a pipeline of other product candidates targeting conditions such as migraine, cocaine dependence, and tick-borne diseases. The company utilizes a proprietary platform technology called Tonix Translational Medicine (TTM) to design new drug products with improved safety, efficacy, and pharmacokinetic properties.


   Company Address: 200 Connell Drive Berkeley Heights 7922 NJ
   Company Phone Number: 799-8599   Stock Exchange / Ticker: NASDAQ TNXP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
PFE   -4.46%    
SNDX   -10.93%    
TGTX   -3.99%    
VRTX   -8.07%    
XNCR   -9.32%    
ZLAB   -10.52%    
• View Complete Report
   



Product Service News

for the Tonix Pharmaceuticals Unveils Groundbreaking TNX-801 Mpox Vaccine Data at World Vaccine Congress Europe...

Published Mon, Oct 20 2025 11:16 AM UTC

Tonix Pharmaceuticals Showcases Promising Data for TNX-801 Mpox Vaccine at the World Vaccine Congress Europe 2025In a significant stride towards combating mpox (formerly known as monkeypox) and smallpox, Tonix Pharmaceuticals announced their presentation of pivotal data on TNX-801, a live virus vaccine investigational candidate, during the World Vaccine Congress Europe 2025...
Clinical Study

The Therapeutic Promise of TNX-102 SL A New Dawn for Fibromyalgia Management Unveiled at the 7th International Congress

Published Sun, Jun 15 2025 12:29 PM UTC

In a noteworthy presentation at the 7th International Congress on Controversies in Fibromyalgia, Tonix Pharmaceuticals showcased groundbreaking data regarding its innovative therapeutic agent, TNX-102 SL. This sublingual formulation of cyclobenzaprine, designed for effective transmucosal delivery, holds the potential for durable therapeutic activity in the challenging landsc...
Product Service News

s with its submission of a New Drug Application (NDA) for TNX-102 SL (sublingual formulation of cyclobenzaprine) to t...

Published Tue, Apr 1 2025 12:06 PM UTC

Advancements in Migraine Management: Tonix Pharmaceuticals Comprehensive Approach through Technology, Education, and Drug DevelopmentMigraine is a debilitating neurological disorder that affects millions of individuals worldwide. With its complex etiology and varied manifestations, the need for innovative solutions to enhance patient management is more crucial than ever. T...
Shares

Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split: A Strategic Move Amidst Market Challenges and Leadership Changes

Published Mon, Feb 3 2025 1:05 PM UTC

Tonix Pharmaceuticals Holding Corp. Implements Reverse Stock Split Amid Leadership Changes and Mixed Market SignalsOn February 3, 2025, Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company known for its innovative products and an array of potential development candidates, announced a significant corporate maneuver a 1-for-100 rev...
Management Changes

Turning the Tide: Tonix Pharmaceuticals Appoints New VP of Market Access Amid Mixed Financial Signals

Published Wed, Jan 8 2025 12:01 PM UTC

In a strategic move aimed at bolstering its market presence, Tonix Pharmaceuticals Holding Corp has announced the appointment of Gary Ainsworth as Vice President of Market Access. Mr. Ainsworth, with over two decades of industry experience, is expected to strengthen the company s commercial leadership team and enhance its strategies in navigating the complexities of market a...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 6.67
Price to Sales (Expected) -
Price to Book 0.87
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.72
Working Capital Ratio 6.35
Leverage Ratio (MRQ) 0.14
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -11.29 $
Revenues (TTM) 1.75 $
Cash Flow (TTM) 3.59 $
Cash 10.59 $
Book Value 13.36 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 204,944
Net Income per Employee (TTM) -1,124,408
Receivable Turnover Ratio (TTM) 3.83
Inventory Turnover Ratio (TTM) 0.83
Asset Turnover Ratio (TTM) 0.11

Profitability Ratios Current
Gross Margin (MRQ) 94.81 %
Operating Margin (MRQ) -314.05 %
Net Margin (MRQ) -299.41 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Tonix Pharmaceuticals Holding's Segments
Tonmya    108.42 % of total Revenue
Zembrace Symtouch    36.37 % of total Revenue
Tosymra    5.99 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.